Tags

Type your tag names separated by a space and hit enter

Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer.
Immunol Invest. 2007; 36(4):371-86.II

Abstract

Many investigators have demonstrated alteration of gastric mucins in H. pylori infected individuals. The inflammatory environment induced by H. pylori leading to aberrant glycosylation of MUC1 and demasking of core peptide MUC1 epitope could enhance immune responses to MUC1. IgG and IgM immune response to MUC1 in patients with gastric cancer (n = 214) chronic gastroduodenal diseases (n = 160) and healthy blood donors (n = 91) was studied with ELISA using bovine serum albumin-MUC1 60-mer peptide as antigen. H. pylori serologic status was evaluated with ELISA and CagA status by immunoblotting. Gastric mucosa histology was scored according to the Sydney system. Compared to H. pylori seronegative individuals, higher levels of IgG antibody to MUC1 were found in H. pylori seropositive patients with benign gastric diseases (p < 0.01) and blood donors (p < 0.03). Higher MUC1 IgG antibody levels were associated with a higher degree of gastric corpus mucosa inflammation in patients with chronic gastroduodenal diseases (p < 0.0025). There was a positive correlation between the levels of anti-H. pylori IgG and MUC1 IgG antibody levels in blood donors (p = 0.03), and in patients with benign diseases (p < 0.0001). In patients with gastric cancer (n = 214) a significantly higher level of anti-MUC1 IgG than in blood donors was observed (p < 0.001) irrespective of H. pylori status or stage of cancer. MUC1 IgM antibody levels were not related to the H. pylori serology. IgG immune response to tumor-associated MUC1 is up regulated in H. pylori infected individuals. This increase is associated with a higher IgG immune response to H. pylori and with a higher degree of gastric mucosa inflammation. High levels of MUC1 IgG antibody irrespective of H. pylori serologic status characterized patients with gastric cancer. The findings suggest that, in some individuals, the H. pylori infection may stimulate immune response to tumor-associated MUC1 peptide antigen thus modulating tumor immunity.

Authors+Show Affiliations

National Institute for Health Development, Tallinn, Estonia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17691020

Citation

Klaamas, K, et al. "Impact of Helicobacter Pylori Infection On the Humoral Immune Response to MUC1 Peptide in Patients With Chronic Gastric Diseases and Gastric Cancer." Immunological Investigations, vol. 36, no. 4, 2007, pp. 371-86.
Klaamas K, Kurtenkov O, von Mensdorff-Pouilly S, et al. Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. Immunol Invest. 2007;36(4):371-86.
Klaamas, K., Kurtenkov, O., von Mensdorff-Pouilly, S., Shljapnikova, L., Miljukhina, L., Brjalin, V., & Lipping, A. (2007). Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. Immunological Investigations, 36(4), 371-86.
Klaamas K, et al. Impact of Helicobacter Pylori Infection On the Humoral Immune Response to MUC1 Peptide in Patients With Chronic Gastric Diseases and Gastric Cancer. Immunol Invest. 2007;36(4):371-86. PubMed PMID: 17691020.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. AU - Klaamas,K, AU - Kurtenkov,O, AU - von Mensdorff-Pouilly,S, AU - Shljapnikova,L, AU - Miljukhina,L, AU - Brjalin,V, AU - Lipping,A, PY - 2007/8/11/pubmed PY - 2007/10/3/medline PY - 2007/8/11/entrez SP - 371 EP - 86 JF - Immunological investigations JO - Immunol. Invest. VL - 36 IS - 4 N2 - Many investigators have demonstrated alteration of gastric mucins in H. pylori infected individuals. The inflammatory environment induced by H. pylori leading to aberrant glycosylation of MUC1 and demasking of core peptide MUC1 epitope could enhance immune responses to MUC1. IgG and IgM immune response to MUC1 in patients with gastric cancer (n = 214) chronic gastroduodenal diseases (n = 160) and healthy blood donors (n = 91) was studied with ELISA using bovine serum albumin-MUC1 60-mer peptide as antigen. H. pylori serologic status was evaluated with ELISA and CagA status by immunoblotting. Gastric mucosa histology was scored according to the Sydney system. Compared to H. pylori seronegative individuals, higher levels of IgG antibody to MUC1 were found in H. pylori seropositive patients with benign gastric diseases (p < 0.01) and blood donors (p < 0.03). Higher MUC1 IgG antibody levels were associated with a higher degree of gastric corpus mucosa inflammation in patients with chronic gastroduodenal diseases (p < 0.0025). There was a positive correlation between the levels of anti-H. pylori IgG and MUC1 IgG antibody levels in blood donors (p = 0.03), and in patients with benign diseases (p < 0.0001). In patients with gastric cancer (n = 214) a significantly higher level of anti-MUC1 IgG than in blood donors was observed (p < 0.001) irrespective of H. pylori status or stage of cancer. MUC1 IgM antibody levels were not related to the H. pylori serology. IgG immune response to tumor-associated MUC1 is up regulated in H. pylori infected individuals. This increase is associated with a higher IgG immune response to H. pylori and with a higher degree of gastric mucosa inflammation. High levels of MUC1 IgG antibody irrespective of H. pylori serologic status characterized patients with gastric cancer. The findings suggest that, in some individuals, the H. pylori infection may stimulate immune response to tumor-associated MUC1 peptide antigen thus modulating tumor immunity. SN - 0882-0139 UR - https://www.unboundmedicine.com/medline/citation/17691020/Impact_of_Helicobacter_pylori_infection_on_the_humoral_immune_response_to_MUC1_peptide_in_patients_with_chronic_gastric_diseases_and_gastric_cancer_ L2 - http://www.tandfonline.com/doi/full/10.1080/08820130601109727 DB - PRIME DP - Unbound Medicine ER -